Brief report: How many patients complete an adequate trial of donepezil?

Catherine M. Roe, Michael J. Anderson, Barney Spivack

Research output: Contribution to journalArticlepeer-review

34 Scopus citations

Abstract

Pharmacy claims data were used to evaluate medication adherence among 59 new users of donepezil aged 65 to 94 years. The probability (± 95% confidence interval) of a new user continuing donepezil at 90 days was .797 ± .103 and at 180 days was .627 ± .124. Additionally, 13.9% of those who continued therapy for at least 180 days showed gaps in treatment of six weeks or more. These results suggest that adherence with donepezil could be improved in clinical practice.

Original languageEnglish
Pages (from-to)49-51
Number of pages3
JournalAlzheimer disease and associated disorders
Volume16
Issue number1
DOIs
StatePublished - Apr 22 2002
Externally publishedYes

Keywords

  • Cognitive disorders/dementia
  • Donepezil
  • Medication adherence

Fingerprint Dive into the research topics of 'Brief report: How many patients complete an adequate trial of donepezil?'. Together they form a unique fingerprint.

Cite this